CohBar Inc (CWBR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CohBar Inc (CWBR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8275
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and CNS disorders. It offers MDP drugs such as MOTS-c for regulation of metabolism and therapeutic potential for diabetes mellitus, obesity, fatty liver and cancers; SHLP-6 for cancer; humanin against Alzheimer’s disease, atherosclerosis, myocardial and cerebral ischemia and diabetes; and SHLP-2 for Alzheimer’s disease. CohBar’s expertise comprises cellular and mitochondrial genetics and biology, metabolism, the biology of aging, drug discovery, development and commercialization. The company also conducts scientific research in the fields of age-related diseases, mitochondrial genomics and biology, longevity, metabolism and MDP’s. CohBar is headquartered in Menlo Park, California, the US.

CohBar Inc (CWBR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CohBar Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CohBar Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CohBar Raises USD0.5 Million in Venture Financing 11
Licensing Agreements 12
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 12
Equity Offering 14
CohBar Raises USD20 Million in Public Offering of Shares 14
CohBar Plans to Raise up to USD100 Million in Public Offering of Securities 15
CohBar Plans to Raise up to USD18.7 Million in Private Placement of Shares 16
CohBar Raises USD5.2 Million in Private Placement of Units 17
CohBar Raises USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 18
CohBar Raises USD11 Million in IPO of Units 19
CohBar Raises USD2.7 Million in Private Placement of Units 20
CohBar Raises USD2.7 Million in Private Placement of Series B Preferred Stock 21
CohBar Raises USD1.8 Million in Private Placement of Series A Preferred Stock 22
Debt Offering 23
CohBar Raises USD1.8 Million in Second and Final Tranche of Private Placement of Promissory Notes 23
CohBar Raises USD2.14 Million in First Tranche of Private Placement of Promissory Notes 24
CohBar Raises USD0.07 Million in Private Placement of Convertibles Notes 25
CohBar Inc – Key Competitors 26
CohBar Inc – Key Employees 27
CohBar Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 14, 2018: CohBar announces second quarter 2018 financial results 29
May 15, 2018: CohBar Reports First Quarter 2018 Financial Results 31
Apr 02, 2018: CohBar Announces Fourth Quarter 2017 Financial Results 32
Nov 13, 2017: CohBar Announces Third Quarter 2017 Financial Results 34
Aug 14, 2017: CohBar Announces Second Quarter 2017 Financial Results 36
May 15, 2017: CohBar Announces First Quarter 2017 Financial Results 37
Mar 22, 2017: CohBar Announces Fourth Quarter 2016 Financial Results 39
Corporate Communications 40
Jun 07, 2018: CohBar Announces the Appointment of Dr. Philippe Calais to its Board 40
Dec 13, 2017: CohBar Announces Approval for Listing on the NASDAQ Capital MarketNASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR 41
Dec 07, 2017: CohBar Announces the Appointment of Dr. John Amatruda to its Board 42
Product News 43
05/29/2018: CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions 43
Clinical Trials 44
Jun 25, 2018: CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions 44
Oct 23, 2017: CohBar Presents Preclinical Data on CB4211 Program for NASH at the AASLD Liver Meeting 2017 45
Oct 04, 2017: CohBar Announces Scientific Presentation on Preclinical data of drug candidate CB-4211 for NASH Study at the AASLD Liver Meeting 2017 46
Feb 21, 2017: CohBar Announces Positive Results from Preclinical NASH Study of CB-4211 47
Other Significant Developments 48
Sep 25, 2018: CohBar engages LifeSci advisors as investor relations partner 48
Jun 27, 2018: CohBar Added to Russell 2000 Index 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
CohBar Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CohBar Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CohBar Raises USD0.5 Million in Venture Financing 11
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 12
CohBar Raises USD20 Million in Public Offering of Shares 14
CohBar Plans to Raise up to USD100 Million in Public Offering of Securities 15
CohBar Plans to Raise up to USD18.7 Million in Private Placement of Shares 16
CohBar Raises USD5.2 Million in Private Placement of Units 17
CohBar Raises USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 18
CohBar Raises USD11 Million in IPO of Units 19
CohBar Raises USD2.7 Million in Private Placement of Units 20
CohBar Raises USD2.7 Million in Private Placement of Series B Preferred Stock 21
CohBar Raises USD1.8 Million in Private Placement of Series A Preferred Stock 22
CohBar Raises USD1.8 Million in Second and Final Tranche of Private Placement of Promissory Notes 23
CohBar Raises USD2.14 Million in First Tranche of Private Placement of Promissory Notes 24
CohBar Raises USD0.07 Million in Private Placement of Convertibles Notes 25
CohBar Inc, Key Competitors 26
CohBar Inc, Key Employees 27

List of Figures
CohBar Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CohBar Inc (CWBR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Investors Heritage Capital Corporation:企業の戦略・SWOT・財務情報
    Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • MakeMyTrip Limited:企業の戦略・SWOT・財務分析
    MakeMyTrip Limited - Strategy, SWOT and Corporate Finance Report Summary MakeMyTrip Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Total SA (FP)-石油・ガス分野:企業M&A・提携分析
    Summary Total S.A. (Total) is an integrated global oil and gas company that produces, refines and markets oil, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distribution of petrole …
  • Kratos Defense & Security Solutions, Inc.:企業の戦略・SWOT・財務情報
    Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kratos Defense & Security Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Optimum General Inc.
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Manhattan Construction Group:企業の戦略的SWOT分析
    Manhattan Construction Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Imperial Oil Ltd (IMO):企業の財務・戦略的SWOT分析
    Imperial Oil Ltd (IMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Staffline Group plc:企業のM&A・事業提携・投資動向
    Staffline Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Staffline Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Laboratory Corp of America Holdings (LH)-製薬・医療分野:企業M&A・提携分析
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Steel Authority of India Ltd:企業のM&A・事業提携・投資動向
    Steel Authority of India Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Steel Authority of India Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Paragon Offshore plc (PGN):企業の財務・戦略的SWOT分析
    Summary Paragon Offshore Plc (Paragon Offshore) is an oil and gas company that offers offshore drilling rigs. The company provides contract drilling, maintenance and fleet management services. It operates through a fleet of rigs including Jackup rigs, Drillships and semi submersible rigs. Paragon Of …
  • Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Me …
  • Uni-President China Holdings Ltd:企業の戦略・SWOT・財務分析
    Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • New York Power Authority:企業の戦略・SWOT・財務分析
    New York Power Authority - Strategy, SWOT and Corporate Finance Report Summary New York Power Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報
    Summary Premier Biomedical Inc (Premier Biomedical) is a drug development company that develops medications for debilitating and fatal illnesses. The company offers Feldetrex, a drug candidate used for the treatment of multiple sclerosis, fibromyalgia, blood sepsis and viremia, and cancer. It develo …
  • Sterigenics International LLC:医療機器:M&Aディール及び事業提携情報
    Summary Sterigenics International LLC (SteriGenics), formerly Radiation Sterilizers Inc, a subsidiary of Gtcr Llc, is a medical device company that offers sterilization technologies such as gamma irradiation, electron beam and ethylene oxide. The company was formerly known as Radiation Sterilizers, …
  • Kobayashi Pharmaceutical Co Ltd (4967)-製薬・医療分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Bangchak Corporation PCL (BCP):企業の財務・戦略的SWOT分析
    Bangchak Corporation PCL (BCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Bank of Yokohama Ltd:企業の戦略・SWOT・財務分析
    The Bank of Yokohama Ltd - Strategy, SWOT and Corporate Finance Report Summary The Bank of Yokohama Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆